Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol
Verheijen, J.H.; Rijken, D.C.; Chang, G.T.; Preston, F.E.; Kluft, C.
Thrombosis and Haemostasis 51(3): 396-397
1984
ISSN/ISBN: 0340-6245 PMID: 6437007 Document Number: 225729
Fibrinolytic activity in plasma euglobulin fractions can be increased by oral administration of stanozolol. This increase is not caused by increased synthesis or release of tissue-type plasminogen activator. A decreased level of fast acting t-PA inhibition is very probably the cause of the higher activity. These results suggest that this inhibition has a regulatory role on fibrinolysis in vivo.
Document emailed within 1 workday
Related Documents
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576Sprengers, E.D.; Akkerman, J.W.; Jansen, B.G. 1986: Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood Thrombosis and Haemostasis 55(3): 325-329
Habib, S.S.; Abdel Gader, A.G.M.; Kurdi, M.I.; Suriya, M.O.; Al Aseri, Z. 2012: Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina JPMA. Journal of the Pakistan Medical Association 62(7): 681-685
Glas-Greenwalt, P.; Hall, J.M.; Panke, T.W.; Kant, K.S.; Allen, C.M.; Pollak, V.E. 1986: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura Journal of Laboratory and Clinical Medicine 108(5): 415-422
De Moerloose, P.; Mermillod, N.; Amiral, J.; Reber, G. 1998: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1 Thrombosis and Haemostasis 79(3): 554-556
Yamada, R.; Yamada, S.; Ishii, A.; Tane, S. 1993: Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy Nippon Ganka Gakkai Zasshi 97(8): 955-960
Fukao, H.; Yamamoto, K.; Matsuo, O. 1991: Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome Rinsho Byori. Japanese Journal of Clinical Pathology 39(7): 720-726
Wallnöfer, A.E.; van Griensven, J.M.; Schoemaker, H.C.; Cohen, A.F.; Lambert, W.; Kluft, C.; Meijer, P.; Kooistra, T. 1993: Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans Thrombosis and Haemostasis 70(6): 1005-1008
Shiba, E.; Kobayashi, T.; Yayoi, E.; Takatsuka, Y.; Koyama, H.; Takai, S.; Mori, T. 1992: Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report Nihon Geka Gakkai Zasshi 93(1): 109
Virji, M.A.; Aggarwal, S.; Kang, Y. 1989: Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation Transplantation Proceedings 21(3): 3540-3541
Kruithof, E.K.; Gudinchet, A.; Bachmann, F. 1988: Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states Thrombosis and Haemostasis 59(1): 7-12
Kobayashi, Y.; Fukuo, Y.; Shibuya, T.; Terashi, A. 1990: The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 27(5): 578-583
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Fujii, S.; Lucore, C.L.; Hopkins, W.E.; Billadello, J.J.; Sobel, B.E. 1990: Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells Thrombosis and Haemostasis 64(3): 412-419
Chen, Z.Y. 1993: A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease Zhonghua Xin Xue Guan Bing Za Zhi 21(3): 163-164; 188
Küçük, M.; Sezer, S.D.; Odabaşi, A.R.; Güner, Z.; Yuksel, H.; Serter, M. 2011: The effect of low-dose combined oral contraceptive containing 100 ug levonorgestrel on plasma plasminogen activator inhibitor-1 concentrations Clinical and Experimental Obstetrics and Gynecology 38(1): 54-56
Boutsikas, G.; Terpos, E.; Markopoulos, A.; Papatheodorou, A.; Stefanou, A.; Georgiou, G.; Galani, Z.; Komninaka, V.; Telonis, V.; Anagnostopoulos, I.; Dimitrakopoulou, L.; Anargyrou, K.; Tsionos, K.; Christoulas, D.; Gonianaki, M.; Giannikos, T.; Kokoris, S.; Konstantopoulos, K.; Meletis, J.; Angelopoulou, M.K.; Travlou, A.; Vassilakopoulos, T.P. 2017: Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL) Journal of BUON: Official Journal of the Balkan Union of Oncology 22(4): 1022-1031
Sattar, N.; McMillan, D.C. 1998: Association between plasma plasminogen activator inhibitor-1 and survival in colorectal cancer. Measuring C reactive protein concentrations may be more useful Bmj 317(7160): 750-751
Davì, G.; Belvedere, M.; Vigneri, S.; Catalano, I.; Giammarresi, C.; Roccaforte, S.; Consoli, A.; Mezzetti, A. 1996: Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus Thrombosis and Haemostasis 76(1): 34-37
Tomasiuk, R.; Mirowski, M.; Wierzbicki, R. 1990: Plasminogen activator (PA) in Guerin epithelioma. Additional PA inhibitor in plasma of rats bearing the epithelioma Neoplasma 37(5): 511-519